Sentence examples for basis of cost-effectiveness from inspiring English sources

Methods based on decision theory are being developed by health economists that can contribute to the design of clinical trials in such a way that they can more effectively lead to better informed drug funding decisions on the basis of cost-effectiveness in addition to clinical outcomes.

If the ideological barnacles on all sides could somehow be scraped off, perhaps the matter could be decided on the basis of cost-effectiveness, economic and diplomatic.

Conclusions: A sequential scheme for the treatment of chronic tinnitus is discussed on the basis of cost-effectiveness considerations.

Until better information becomes available, it is not possible to distinguish between the two β-blockers on the basis of cost-effectiveness.

Knowing the benefits and costs of a M&R strategy, asset managers can compare the overall desirability of alternative treatments or strategies and select the best alternative on the basis of cost-effectiveness [28].

Three Indian medicinal plants, M. balbisiana (banana), A. indica (neem) and O. tenuiflorum (black tulsi), were selected from West Bengal, India, on the basis of cost-effectiveness, ease of availability and medicinal property.

Insulation, good construction practices, effective use of vegetation/trees, and passive solar heating should all be used to promote sustainable energy practices and all will be justified on the basis of cost effectiveness.

In the United Kingdom, it is routinely available for patients aged 70, with a catch-up campaign for 72-79 year olds (on the basis of cost effectiveness studies 5); the current catch-up cohort is those aged 79.

The SMC and NICE single technology appraisals of sorafenib for advanced HCC recommended that the drug should not be available on the basis of cost effectiveness (National Institute for Health and Clinical Excellence and Scottish Medicines Consortium websites).

On the basis of cost effectiveness, the study seeks to challenge the current reliance on clinical diagnosis as opposed to the introduction of malaria confirmatory diagnostic methods in this era of ACTs.

The scope of the funding includes: 1) drug/indication combinations appraised by NICE and not recommended on the basis of cost effectiveness, or where the recommendations restrict access to a smaller group of patients than the specifications set out in the marketing authorization; and 2) drug/indication combinations for which NICE has not, or not yet, issued guidance.